Research ArticleSystemic Lupus Erythematosus

Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort

Manuel F. Ugarte-Gil, Daniel Wojdyla, Guillermo J. Pons-Estel, Rosana Quintana, José A. Gómez-Puerta, Luis J. Catoggio, Alejandro Alvarellos, Verónica Saurit, Eduardo Borba, Emilia Sato, Lilian Costallat, Nilzio A. Da Silva, Antonio Iglesias-Gamarra, Oscar Neira, Gil Reyes-Llerena, Mario H. Cardiel, Mary Carmen Amigo, Eduardo Acevedo-Vásquez, María H. Esteva-Spinetti, Graciela S. Alarcón and Bernardo A. Pons-Estel
The Journal of Rheumatology October 2019, 46 (10) 1299-1308; DOI: https://doi.org/10.3899/jrheum.180433

REFERENCES

  1. 1.↵
    1. Ugarte-Gil MF,
    2. Burgos PI,
    3. Alarcon GS
    . Treat to target in systemic lupus erythematosus: a commentary. Clin Rheumatol 2016;35:1903–7.
    OpenUrl
  2. 2.↵
    1. van Vollenhoven RF,
    2. Mosca M,
    3. Bertsias G,
    4. Isenberg D,
    5. Kuhn A,
    6. Lerstrom K,
    7. et al.
    Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis 2014;73:958–67.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Ugarte-Gil MF,
    2. Wojdyla D,
    3. Pons-Estel GJ,
    4. Catoggio LJ,
    5. Drenkard C,
    6. Sarano J,
    7. et al.
    Remission and low disease activity status (LDAS) protect lupus patients from damage occurrence: Data from a multiethnic, multinational Latin American lupus cohort (GLADEL). Ann Rheum Dis 2017;76:2071–4.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Urowitz MB,
    2. Feletar M,
    3. Bruce IN,
    4. Ibanez D,
    5. Gladman DD
    . Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005;32:1467–72.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Ko K,
    2. Levine AB,
    3. Griffin R,
    4. Dvorkina O,
    5. Sheikh S,
    6. Yazdany J,
    7. et al.
    Baseline predictors of remission and low disease activity using recently defined international criteria in a multi-center lupus registry cohort [abstract]. Arthritis Rheumatol 2015;67 Suppl 10:2938.
    OpenUrl
  6. 6.↵
    1. Zen M,
    2. Iaccarino L,
    3. Gatto M,
    4. Bettio S,
    5. Nalotto L,
    6. Ghirardello A,
    7. et al.
    Prolonged remission in Caucasian patients with SLE: Prevalence and outcomes. Ann Rheum Dis 2015;74:2117–22.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Tsang-A-Sjoe MW,
    2. Bultink IE,
    3. Heslinga M,
    4. Voskuyl AE
    . Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology 2017;56:121–8.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Franklyn K,
    2. Lau CS,
    3. Navarra SV,
    4. Louthrenoo W,
    5. Lateef A,
    6. Hamijoyo L,
    7. et al.
    Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis 2016;79:1615–21.
    OpenUrl
  9. 9.↵
    1. Steiman AJ,
    2. Urowitz MB,
    3. Ibanez D,
    4. Papneja A,
    5. Gladman DD
    . Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol 2014;41:1808–16.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Polachek A,
    2. Gladman DD,
    3. Su J,
    4. Urowitz MB
    . Defining low disease activity in systemic lupus erythematosus. Arthritis Care Res 2017;69:997–1003.
    OpenUrl
  11. 11.↵
    1. Zen M,
    2. Iaccarino L,
    3. Gatto M,
    4. Saccon F,
    5. Larosa M,
    6. Ghirardello A,
    7. et al.
    Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis 2018;77:104–10.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. van Vollenhoven R,
    2. Voskuyl A,
    3. Bertsias G,
    4. Aranow C,
    5. Aringer M,
    6. Arnaud L,
    7. et al.
    A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017;76:554–61.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Pons-Estel GJ,
    2. Catoggio LJ,
    3. Cardiel MH,
    4. Bonfa E,
    5. Caeiro F,
    6. Sato E,
    7. et al.
    Lupus in Latin-American patients: lessons from the GLADEL cohort. Lupus 2015;24:536–45.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Shinjo SK,
    2. Bonfa E,
    3. Wojdyla D,
    4. Borba EF,
    5. Ramirez LA,
    6. Scherbarth HR,
    7. et al.
    Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010;62:855–62.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Bombardier C,
    2. Gladman DD,
    3. Urowitz MB,
    4. Caron D,
    5. Chang CH
    . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630–40.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Mendez Castellano H,
    2. de Méndez MC
    . Sociedad y estratificación: Método Graffar-Méndez Castellano. Caracas: Fundacredesa; 1994.
  17. 17.↵
    1. Gladman D,
    2. Ginzler E,
    3. Goldsmith C,
    4. Fortin P,
    5. Liang M,
    6. Urowitz M,
    7. et al.
    The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363–9.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Medina-Quinones CV,
    2. Ramos-Merino L,
    3. Ruiz-Sada P,
    4. Isenberg D
    . Analysis of complete remission in systemic lupus erythematosus patients over a 32-year period. Arthritis Care Res 2016;68:981–7.
    OpenUrl
  19. 19.↵
    1. Mok CC,
    2. Ho LY,
    3. Tse SM,
    4. Chan KL
    . Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus. Ann Rheum Dis 2017;76:1420–5.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Wilhelm TR,
    2. Magder LS,
    3. Petri M
    . Remission in systemic lupus erythematosus: durable remission is rare. Ann Rheum Dis 2017;76:547–53.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Golder V,
    2. Kandane-Rathnayake R,
    3. Hoi AY,
    4. Huq M,
    5. Louthrenoo W,
    6. An Y,
    7. et al.
    Frequency and predictors of the lupus low disease activity state in a multi-national and multiethnic cohort. Arthritis Res Ther 2016;18:260.
    OpenUrl
  22. 22.↵
    1. Formiga F,
    2. Moga I,
    3. Pac M,
    4. Mitjavila F,
    5. Rivera A,
    6. Pujol R
    . High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus. Rheumatology 1999;38:724–7.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Sutton EJ,
    2. Davidson JE,
    3. Bruce IN
    . The Systemic Lupus International Collaborating Clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum 2013;43:352–61.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

SYSTEMIC LUPUS ERYTHEMATOSUS
REMISSION
LOW DISEASE ACTIVITY STATE
RISK FACTORS

Keywords